Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT05745311
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Kunming Pharmaceuticals, Inc.
- Registry
-
NCT05745311
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05745311. Randomized; triple masking; primary purpose treatment. Start 2023-03-01 (anticipated); primary completion 2024-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- The KPCXM18 injection
- Intervention (Drug)
- Placebo
- Lead sponsor
- Kunming Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct05745311- Content hash
287d374e48998ce2bd51405e4c5b66e247ffb5a2b146d58bae8704235a441009